RHYTHM METABOLIC
Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.
RHYTHM METABOLIC
Industry:
Developer Platform Health Care Pharmaceutical
Founded:
2013-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Total Employee:
11+
Status:
Active
Total Funding:
40 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Founder
Investors List
Ipsen
Ipsen investment in Series A - Rhythm Metabolic
OrbiMed
OrbiMed investment in Series A - Rhythm Metabolic
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - Rhythm Metabolic
Deerfield
Deerfield investment in Series A - Rhythm Metabolic
MPM Capital
MPM Capital investment in Series A - Rhythm Metabolic
New Enterprise Associates
New Enterprise Associates investment in Series A - Rhythm Metabolic
Third Rock Ventures
Third Rock Ventures investment in Series A - Rhythm Metabolic
Wellington Management
Wellington Management investment in Series A - Rhythm Metabolic